Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Vertex’s Matt Emmens on His Journey From Security Guard to CEO
|
Luke Timmerman |
01/27/10 |
Boston
|
|
Merck’s Alan Sachs, on RNAi’s Big Challenge: Delivery, Delivery, Delivery
|
Luke Timmerman |
01/21/10 |
National
|
|
ZymoGenetics Regains Full U.S. Rights to Recothrom as Bayer Walks Away
|
Luke Timmerman |
12/21/09 |
Seattle
|
|
Anadys Hepatitis C Drug Shows Early Sign of Viral-Killing Punch, Without Dreaded Rash
|
Luke Timmerman |
12/17/09 |
San Diego
|
|
The Top Five Biotech Innovations of the 2000s
|
Clay Siegall |
12/15/09 |
Seattle
|
|
Vertex Snags Extra $58M
|
Luke Timmerman |
12/04/09 |
Boston
|
|
ZymoGenetics Axes 52 Jobs, Quits Discovery of Immunology Drugs, to Conserve Cash
|
Luke Timmerman |
12/03/09 |
Seattle
|
|
Vertex Raises $443M in Yet Another Monster Stock Sale
|
Luke Timmerman |
12/03/09 |
Boston
|
|
Ocera Therapeutics, Pursuing New Drug for Liver, Hopes to Help People Stay Mentally Sharp
|
Luke Timmerman |
11/25/09 |
San Diego
|
|
Vertex Turns $109M Debt Into Stock
|
Luke Timmerman |
11/10/09 |
Boston
|
|
Alder Scores Deal With Bristol-Myers Potentially Worth $1 Billion
|
Luke Timmerman |
11/10/09 |
Seattle
|
|
Amylin Forms Global Alliance in Obesity Drug Development; TEDMED’s Show Will Go On, Sequenom Sued for Civil Fraud, & More San Diego Biotech News
|
Bruce V. Bigelow |
11/05/09 |
San Diego
|
|
Combination Drugs Are The Future for Hepatitis C
|
Steve Worland |
11/03/09 |
San Diego
|
|
Vertex Hepatitis C Drug Passes Key Test With More Convenient, Twice-Daily Dose
|
Luke Timmerman |
10/31/09 |
Boston
|
|
Idenix Shares Drop as Novartis Walks Away From Hepatitis C Drug
|
Luke Timmerman |
10/30/09 |
Boston
|
|
ZymoGenetics Rival Emerges, Omeros IPO Casts Shadow, Microsoft’s HealthVault Seeks Users, & More Seattle Area Life Sciences News
|
Luke Timmerman |
10/29/09 |
Seattle
|
|
Vertex Hepatitis C Drug Wipes Out Virus For Toughest-to-Treat Patients
|
Luke Timmerman |
10/28/09 |
Boston
|
|
Zymo Gets $70M for Starting Trial
|
Luke Timmerman |
10/27/09 |
Seattle
|
|
Vertex Raises $155M Through Debt Financing for Hepatitis C Drug in Europe
|
Ryan McBride |
09/30/09 |
Boston
|
|
ZymoGenetics Partner Halts Multiple Sclerosis Trials After Drug Fails
|
Luke Timmerman |
09/28/09 |
Seattle
|
|
MicroRNA Drug Developer Santaris Establishes Toehold in San Diego With Isis Veteran
|
Luke Timmerman |
09/16/09 |
San Diego
|
|
Arena Prepares to Release Big Obesity Study, Minnow Medical Goes Into ‘Commercialization Mode,’ Metabasis Hires Strategic Adviser, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
09/10/09 |
San Diego
|
|
Anadys Starts Hep C Trial
|
Luke Timmerman |
09/09/09 |
San Diego
|
|
Anadys, Biotech’s Roller Coaster Story, Gears Up for Next Big Step with Hepatitis C Drug
|
Luke Timmerman |
08/19/09 |
San Diego
|
|
Anadys Cleared to Start HepC Trial
|
Luke Timmerman |
07/30/09 |
San Diego
|
|
Vertex Grabs $105M in Amended Telaprevir Deal with Mitsubishi
|
Ryan McBride |
07/30/09 |
Boston
|
|
Alnylam and Isis’ Offspring, Regulus, Keeps Pushing on Biology’s ‘Bleeding Edge’
|
Luke Timmerman |
07/28/09 |
San Diego
|
|
Vertex Selling Telaprevir Payment Rights
|
Ryan McBride |
07/10/09 |
Boston
|
|
Anadys Cuts Jobs, Obesity Drug Developers Show Intriguing Results, Trius Antibiotic Passes Key Test, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
06/11/09 |
San Diego
|
|
Anadys Pharma Cuts 40% of Workforce and Raises $17.5M to Stay Afloat
|
Ryan McBride |
06/04/09 |
San Diego
|
|
Page 1 of
3 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
